CD47 and neoplasm: On the other hand, CD47-SIRPα pathway blockers were found to enhance the ability of macrophages to attack tumor cells, as it is stated that CD47 is overexpressed on cancer cells and inhibits macrophage-mediated phagocytosis (89).